Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4004258 | 0.73 | RAB9A (0.56) | RAB9ALMNAALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL7529821 | 0.71 | RAB9A (0.54) | RAB9ALMNAALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL1978418 | 0.68 | RAB9A (0.50) | RAB9ALMNAALDH1A1POLB | |
| SCHEMBL3441643 | 0.68 | RAB9A (1.00) | RAB9ALMNAALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL11516807 | 0.68 | RAB9A (0.50) | RAB9ALMNAALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL9866849 | 0.67 | RAB9A (0.53) | RAB9ALMNAALDH1A1POLB | |
| SCHEMBL4357488 | 0.67 | RAB9A (0.74) | RAB9ALMNAALDH1A1POLB | |
| SCHEMBL11516141 | 0.67 | RAB9A (0.49) | RAB9ALMNAALDH1A1POLB | |
| SCHEMBL6420028 | 0.66 | RAB9A (0.44) | RAB9ALMNAALDH1A1POLB | |
| SCHEMBL1991375 | 0.65 | RAB9A (0.66) | RAB9ALMNAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247027-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-11 | — | — | US | disclosed |
| US-20240116930-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-11 | — | — | US | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20220213095-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-07 | — | — | US | disclosed |
| US-20220213095-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-07 | — | — | US | disclosed |
| US-11225478-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-18 | — | — | US | disclosed |
| US-20200325138-A1 | P2X7 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-15 | — | — | US | disclosed |
| US-10703749-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-07 | — | — | US | disclosed |
| US-20140275015-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275015-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| EP-1589969-A4 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7265128-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20060069116-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-03-30 | — | — | US | disclosed |
| EP-1589969-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co. Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6908926-B1 | Substituted imidazoles, their preparation and use | NOVO NORDISK A/S (DK) | 2005-06-21 | — | — | US | disclosed |
| WO-2004064778-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO. INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| EP-1173438-A1 | SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000063208-A1 | SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325138-A1 | P2X7 Modulators | P2RX2, P2RX7, P2RY2 | RAB9A 3242/4885LMNA 2272/4885ALDH1A1 1628/4885 |
| US-12247027-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | RAB9A 3242/4885LMNA 2272/4885ALDH1A1 1628/4885 |
| US-11225478-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | RAB9A 3242/4885LMNA 2272/4885ALDH1A1 1628/4885 |
| US-20060069116-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | RAB9A 4575/4885LMNA 3093/4885ALDH1A1 686/4885 |
| US-11820770-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | RAB9A 3242/4885LMNA 2272/4885ALDH1A1 1628/4885 |
| US-20220213095-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | RAB9A 3242/4885LMNA 2272/4885ALDH1A1 1628/4885 |
| US-20240116930-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | RAB9A 3242/4885LMNA 2272/4885ALDH1A1 1628/4885 |
| US-10703749-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | RAB9A 3242/4885LMNA 2272/4885ALDH1A1 1628/4885 |
| US-20140275015-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | RAB9A 3242/4885LMNA 2272/4885ALDH1A1 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.